logo
Local Congressmen reintroduce train derailment bill

Local Congressmen reintroduce train derailment bill

Yahoo11-02-2025
EAST PALESTINE, Ohio (WKBN)- Two Valley Congressmen have reintroduced a bill that would study the long-term health impacts of the East Palestine train derailment.
Congressmen Dave Joyce and Michael Rulli and two democrats reintroduced the bill last week. It has been referred to the House Committee on Energy and Commerce.
The East Palestine Health Impact Act calls for a five-year study on the long-term health impacts caused by the derailment.
Joyce introduced the same legislation last year, but it never got a hearing in the committee.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential
Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential

Yahoo

timean hour ago

  • Yahoo

Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential

SAN DIEGO and CALGARY, AB, July 23, 2025 /CNW/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, hosted a key opinion leader (KOL) webinar featuring leading physicians in the fields of oncology and immunotherapy discussing pelareorep's robust clinical data and how it fits in the evolving treatment landscape for pancreatic and gastrointestinal (GI) cancers. The KOLs provided individual presentations and then participated in a roundtable Q&A discussion. A replay of the full conversation can be found by clicking here. A selection of key takeaways includes: The meaningful survival benefit demonstrated by pelareorep-based treatment combinations in first-line (1L) metastatic pancreatic ductal adenocarcinoma (mPDAC) patients across randomized and single-arm clinical studies necessitates evaluating pelareorep in a registration-enabling study in 1L mPDAC. Immunotherapies have not yet been approved to treat mPDAC patients, illustrating an unmet need, which provides an opportunity for an immunologically active agent like pelareorep to deliver an impactful clinical benefit in this challenging indication. The combination of pelareorep and chemotherapy would be an appealing treatment option for 1L mPDAC patients, even with the presence of RAS inhibitors in the treatment paradigm. Translational data from multiple mPDAC and colorectal cancer clinical trials validate pelareorep's mechanism of action, showing that it replicates in tumors, stimulates chemokine expression, and induces the expansion of tumor-infiltrating lymphocytes (TILs), which correlates with a reduction in tumor size. "I want to thank our esteemed panel of oncologists for their meaningful contributions to our KOL event," said Jared Kelly, Chief Executive Officer of Oncolytics. "Their insights underscore a critical and timely message: pelareorep is a compelling immunotherapy platform that is well situated for combination strategies and a highly differentiated asset for pharma partners looking to expand or establish leadership in GI oncology. We are committed to moving forward aggressively toward registrational development while engaging with partners who share our vision of transforming outcomes in these difficult-to-treat cancers." About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For more about Oncolytics, please visit: or follow the company on social media on LinkedIn and on X @oncolytics. This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential, mechanism of action and benefits of pelareorep as a cancer therapeutic; our commitment to moving forward aggressively toward registrational development while engaging with partners who share our vision of transforming outcomes in these difficult-to-treat cancers; our plans to advance pelareorep into registration enabling studies in metastatic breast cancer and pancreatic cancer; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. We may incur expenses or delays relating to events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws. Company Contact Jon PattonDirector of IR & Communicationjpatton@ Investor Relations for Oncolytics Mike MoyerLifeSci Advisors+1-617-308-4306mmoyer@ Media Contact for Oncolytics Owen BlaschakLifeSci Communicationsoblaschak@ Logo - View original content to download multimedia: SOURCE Oncolytics Biotech® Inc. View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Adia Nutrition Inc. Supports Heroes and Their Families with TRICARE In-Network Application, Advancing Regenerative Care Through Adia Med
Adia Nutrition Inc. Supports Heroes and Their Families with TRICARE In-Network Application, Advancing Regenerative Care Through Adia Med

Yahoo

time2 hours ago

  • Yahoo

Adia Nutrition Inc. Supports Heroes and Their Families with TRICARE In-Network Application, Advancing Regenerative Care Through Adia Med

Winter Park, Florida--(Newsfile Corp. - July 23, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a publicly traded leader in regenerative medicine and personalized wellness solutions, is thrilled to announce that its medical subsidiary, Adia Med, has officially filed to become an in-network provider with TRICARE, the healthcare program serving approximately 9.5 million active-duty service members, retirees, National Guard and Reserve members, and their families worldwide. This step, paired with Adia Med's anticipated approval as a United Healthcare provider by August 1, 2025, positions the company to transform healthcare access for millions. Adia Med expects to secure TRICARE in-network provider status by August 31, 2025, tapping into a program that paid out $50.6 billion for medical treatments in FY2019 to support its beneficiaries. Evaluation of the TRICARE Program: Fiscal Year 2019 Report to Congress. To view an enhanced version of this graphic, please visit: This strategic filing positions Adia Med to serve TRICARE's extensive network of beneficiaries, including military personnel and their families, by offering innovative regenerative treatments such as Umbilical Cord Blood Stem Cell (UCB-SC) therapies, Autologous Hematopoietic Stem Cell Transplantation (AHSCT), and Therapeutic Plasma Exchange (TPE). These therapies, provided at Adia Med's Winter Park clinic and planned satellite locations, target conditions like Multiple Sclerosis, joint pain, torn tendons, and other orthopedic and wellness needs, aligning with Adia Nutrition's mission to revolutionize healthcare accessibility. "We're fired up to support the 9.5 million TRICARE beneficiaries, including our nation's military heroes and their families, by bringing our regenerative therapies into their reach," said Larry Powalisz, CEO of Adia Nutrition Inc. "With TRICARE's massive $50.6 billion investment in medical care, our filing to join their network, alongside our imminent United Healthcare approval, will make advanced treatments more accessible and affordable, driving transformative health outcomes and fueling Adia Med's growth." The TRICARE filing complements Adia Med's recent progress with United Healthcare, where the company has already begun submitting its first patient insurance claims, signaling near-final integration. By securing in-network status with both TRICARE and United Healthcare, Adia Med will join an elite group of providers meeting rigorous standards for clinical excellence, compliance, and patient care. These partnerships will enable insurance reimbursement for Adia Med, enhancing affordability and accessibility for patients seeking innovative treatments. For questions, inquiries or further information, please contact Larry Powalisz at ceo@ or 321-788-0850. About ADIA Nutrition Inc.:Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Website: Website: (X): @ADIA_Nutrition Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise. To view the source version of this press release, please visit Sign in to access your portfolio

FDA Issues Highest Risk Warning for Tofu Recall
FDA Issues Highest Risk Warning for Tofu Recall

Newsweek

time2 hours ago

  • Newsweek

FDA Issues Highest Risk Warning for Tofu Recall

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A recall of tofu due to the potential presence of an undeclared allergen has been issued the highest risk warning by the U.S. Food and Drug Administration (FDA). Shang Hao Jia, Inc., based in California, issued a voluntary recall for a select number of cases of Danshi Spicy Shredded Tofu on June 26 due to possible undeclared sesame. The FDA subsequently issued a Class 1 risk classification for the recall on July 17. Newsweek reached out to Shang Hao Jia, Inc. for comment by phone outside of regular working hours. Why It Matters A Class I risk classification represents "a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death," according to the FDA. The FDA warned in its recall notice that individuals with an allergy or severe sensitivity to sesame "run the risk of serious or life-threatening allergic reaction if they consume this product." Sesame is one of the nine major food allergens as defined in law. The others are milk, eggs, fish, crustacean shellfish, tree nuts, peanuts, wheat and soybeans. Allergic reactions vary in severity from mild symptoms, such as hives and lip swelling, to life-threatening complications, such as anaphylaxis, that may include fatal respiratory problems. Stock image of tofu on a plate. Stock image of tofu on a plate. Arno Burgi/picture-alliance/dpa/AP Images What To Know The product impacted by the recall is the following: Danshi Spicy Shredded Tofu - UPC code: 6 942849 709499 - lot code: 20240825 - best-by date: 05/24/2025 The product was imported by Shang Hao Jia, Inc., and manufactured in China by Sichuan Shifang Danshi Food Co., Ltd. The recall impacts a total of 50 cases, each containing 30 bags. The products were distributed to three grocery stores in the Los Angeles area, according to the recall notice. As of June 27, no illnesses had been reported in connection with the consumption of the products. The recall was initiated after it was discovered during an FDA inspection that the product contained sesame, which was not listed on the packaging. What People Are Saying The FDA says on its website: "People with food allergies should read labels and avoid the foods they are allergic to. The law requires that food labels identify the food source of all major food allergens used to make the food." Dr. Sebastian Lighvani, director of New York Allergy & Asthma PLLC, previously told Newsweek: "Every three minutes in the United States, someone ends up in an emergency room because of an allergic reaction after accidental ingestion of food. So even when we try hard, these reactions are happening. And if you look at the incidence of anaphylaxis, it has skyrocketed in the last five, 10, 20 years. And in the U.S., there's like a 300 to 400 percent increase in the rates of anaphylaxis to foods." What Happens Next The recall is listed as ongoing, according to the FDA. Consumers who purchased the affected product are urged to return it to the place of purchase for a full refund.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store